These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32959366)

  • 1. Gut microbiota-derived trimethylamine N-oxide is associated with poor prognosis in patients with heart failure.
    Li W; Huang A; Zhu H; Liu X; Huang X; Huang Y; Cai X; Lu J; Huang Y
    Med J Aust; 2020 Oct; 213(8):374-379. PubMed ID: 32959366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.
    Winther SA; Øllgaard JC; Tofte N; Tarnow L; Wang Z; Ahluwalia TS; Jorsal A; Theilade S; Parving HH; Hansen TW; Hazen SL; Pedersen O; Rossing P
    Diabetes Care; 2019 Aug; 42(8):1512-1520. PubMed ID: 31123156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimethylamine N-oxide and prognosis in acute heart failure.
    Suzuki T; Heaney LM; Bhandari SS; Jones DJ; Ng LL
    Heart; 2016 Jun; 102(11):841-8. PubMed ID: 26869641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimethylamine-N-oxide (TMAO) predicts fatal outcomes in community-acquired pneumonia patients without evident coronary artery disease.
    Ottiger M; Nickler M; Steuer C; Odermatt J; Huber A; Christ-Crain M; Henzen C; Hoess C; Thomann R; Zimmerli W; Mueller B; Schuetz P
    Eur J Intern Med; 2016 Dec; 36():67-73. PubMed ID: 27567042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.
    Tang WH; Wang Z; Kennedy DJ; Wu Y; Buffa JA; Agatisa-Boyle B; Li XS; Levison BS; Hazen SL
    Circ Res; 2015 Jan; 116(3):448-55. PubMed ID: 25599331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis.
    Tang WH; Wang Z; Fan Y; Levison B; Hazen JE; Donahue LM; Wu Y; Hazen SL
    J Am Coll Cardiol; 2014 Nov; 64(18):1908-14. PubMed ID: 25444145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure.
    Trøseid M; Ueland T; Hov JR; Svardal A; Gregersen I; Dahl CP; Aakhus S; Gude E; Bjørndal B; Halvorsen B; Karlsen TH; Aukrust P; Gullestad L; Berge RK; Yndestad A
    J Intern Med; 2015 Jun; 277(6):717-26. PubMed ID: 25382824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Plasma Measures of Trimethylamine N-Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community-Based Older Adults.
    Lee Y; Nemet I; Wang Z; Lai HTM; de Oliveira Otto MC; Lemaitre RN; Fretts AM; Sotoodehnia N; Budoff M; DiDonato JA; McKnight B; Tang WHW; Psaty BM; Siscovick DS; Hazen SL; Mozaffarian D
    J Am Heart Assoc; 2021 Sep; 10(17):e020646. PubMed ID: 34398665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis.
    Schiattarella GG; Sannino A; Toscano E; Giugliano G; Gargiulo G; Franzone A; Trimarco B; Esposito G; Perrino C
    Eur Heart J; 2017 Oct; 38(39):2948-2956. PubMed ID: 29020409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF.
    Suzuki T; Yazaki Y; Voors AA; Jones DJL; Chan DCS; Anker SD; Cleland JG; Dickstein K; Filippatos G; Hillege HL; Lang CC; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Zwinderman AH; Metra M; Ng LL
    Eur J Heart Fail; 2019 Jul; 21(7):877-886. PubMed ID: 30370976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma trimethylamine n-oxide is associated with renal function in patients with heart failure with preserved ejection fraction.
    Guo F; Qiu X; Tan Z; Li Z; Ouyang D
    BMC Cardiovasc Disord; 2020 Aug; 20(1):394. PubMed ID: 32859154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction.
    Zhou X; Jin M; Liu L; Yu Z; Lu X; Zhang H
    ESC Heart Fail; 2020 Feb; 7(1):188-193. PubMed ID: 31960610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut, microbiota-dependent trimethylamine-N-oxide is associated with long-term all-cause mortality in patients with exacerbated chronic obstructive pulmonary disease.
    Ottiger M; Nickler M; Steuer C; Bernasconi L; Huber A; Christ-Crain M; Henzen C; Hoess C; Thomann R; Zimmerli W; Mueller B; Schuetz P
    Nutrition; 2018 Jan; 45():135-141.e1. PubMed ID: 28870405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of trimethylamine
    Zhang P; Zou JZ; Chen J; Tan X; Xiang FF; Shen B; Hu JC; Wang JL; Wang YQ; Yu JB; Nie YX; Chen XH; Yu JW; Zhang Z; Lv WL; Xie YQ; Cao XS; Ding XQ
    Ren Fail; 2020 Nov; 42(1):1004-1014. PubMed ID: 32985309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota-dependent trimethylamine N-oxide and all-cause mortality: Findings from an updated systematic review and meta-analysis.
    Farhangi MA
    Nutrition; 2020 Oct; 78():110856. PubMed ID: 32592979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors.
    Li XS; Obeid S; Klingenberg R; Gencer B; Mach F; Räber L; Windecker S; Rodondi N; Nanchen D; Muller O; Miranda MX; Matter CM; Wu Y; Li L; Wang Z; Alamri HS; Gogonea V; Chung YM; Tang WH; Hazen SL; Lüscher TF
    Eur Heart J; 2017 Mar; 38(11):814-824. PubMed ID: 28077467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure.
    Tang WH; Wang Z; Shrestha K; Borowski AG; Wu Y; Troughton RW; Klein AL; Hazen SL
    J Card Fail; 2015 Feb; 21(2):91-6. PubMed ID: 25459686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimethylamine-N-oxide (TMAO) predicts short- and long-term mortality and poor neurological outcome in out-of-hospital cardiac arrest patients.
    Hochstrasser SR; Metzger K; Vincent AM; Becker C; Keller AKJ; Beck K; Perrig S; Tisljar K; Sutter R; Schuetz P; Bernasconi L; Neyer P; Marsch S; Hunziker S
    Clin Chem Lab Med; 2020 Aug; 59(2):393-402. PubMed ID: 32866111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies.
    Heianza Y; Ma W; Manson JE; Rexrode KM; Qi L
    J Am Heart Assoc; 2017 Jun; 6(7):. PubMed ID: 28663251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimethylamine N-Oxide and Mortality Risk in Patients With Peripheral Artery Disease.
    Senthong V; Wang Z; Fan Y; Wu Y; Hazen SL; Tang WH
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.